login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
AKARI THERAPEUTICS PLC-ADR (AKTX) Stock News
USA
- NASDAQ:AKTX -
US00972G2075
-
ADR
0.7801
USD
-0.04 (-4.85%)
Last: 10/16/2025, 3:07:09 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
AKTX Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: Benzinga
- Mentions:
OMER
SSKN
EYPT
GNPX
...
12 Health Care Stocks Moving In Wednesday's Intraday Session
7 days ago - By: Akari Therapeutics Plc
Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1
13 days ago - By: Akari Therapeutics Plc
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
22 days ago - By: Benzinga
- Mentions:
QURE
AYTU
SSKN
CLPT
...
12 Health Care Stocks Moving In Wednesday's Intraday Session
10 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Announces Key Leadership Appointments
22 days ago - By: Akari Therapeutics Plc
Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
a month ago - By: Akari Therapeutics Plc
Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
a month ago - By: Akari Therapeutics Plc
Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
a month ago - By: Akari Therapeutics Plc
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
2 months ago - By: Akari Therapeutics Plc
Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
3 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
3 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
3 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
3 months ago - By: ACCESS Newswire
- Mentions:
AMIX
CNSP
NVNO
GRI
...
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
4 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India
5 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
5 months ago - By: Akari Therapeutics Plc
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
5 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
6 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology
6 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala
6 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
7 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer
8 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
9 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Joins Webull Corporate Connect Service Platform
10 months ago - By: Akari Therapeutics Plc
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer
a year ago - By: Akari Therapeutics Plc
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
a year ago - By: Akari Therapeutics Plc
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
a year ago - By: Akari Therapeutics Plc
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
a year ago - By: Akari Therapeutics Plc
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
a year ago - By: Akari Therapeutics Plc
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
a year ago - By: Akari Therapeutics Plc
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
a year ago - By: Akari Therapeutics Plc
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
Please enable JavaScript to continue using this application.